|Articles|June 22, 2016

CenterWatch Joins WIRB-Copernicus Group

WIRB-Copernicus Group has acquired clinical trials information provider CenterWatch, and added its founder and owner, Kenneth A. Getz, to WCG’s board of directors.

WIRB-Copernicus Group has acquired clinical trials information provider CenterWatch, and added its founder and owner, Kenneth A. Getz, to WCG’s board of directors. According to WCG, the acquisition will facilitate an increase in sharing of knowledge and communication among key stakeholders in clinical research.

Read the full release here

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

eClinical Technology: Misconceptions, Challenges, and Opportunities
September 9th 2025
Phase III EMPOWER-Lung 3 Trial Confirms Five-Year Survival Benefit With Libtayo Plus Chemotherapy in NSCLC
September 9th 2025
Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial
September 9th 2025
AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer
September 9th 2025
How Sponsors Can Modernize Tools to Support Physicians
September 9th 2025
Beyond the Algorithm: How Human-Centered AI Design Can Drive Clinical Trial Success
September 8th 2025

CenterWatch Joins WIRB-Copernicus Group

Newsletter

Related Articles

Trending on Applied Clinical Trials Online

AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer

Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19

Phase III EMPOWER-Lung 3 Trial Confirms Five-Year Survival Benefit With Libtayo Plus Chemotherapy in NSCLC

Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial

Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer